Bodini Antonella, Michelucci Elena, Di Giorgi Nicoletta, Caselli Chiara, Signore Giovanni, Neglia Danilo, Smit Jeff M, Scholte Arthur J H A, Mincarone Pierpaolo, Leo Carlo G, Pelosi Gualtiero, Rocchiccioli Silvia
Institute for Applied Mathematics and Information Technologies "E. Magenes," National Research Council, Milan, Italy.
Institute of Clinical Physiology, National Research Council, Pisa, Italy.
Front Cardiovasc Med. 2021 Jul 16;8:682785. doi: 10.3389/fcvm.2021.682785. eCollection 2021.
Lipidomics is emerging for biomarker discovery in cardiovascular disease, and circulating lipids are increasingly incorporated in risk models to predict cardiovascular events. Moreover, specific classes of lipids, such as sphingomyelins, ceramides, and triglycerides, have been related to coronary artery disease (CAD) severity and plaque characteristics. To avoid unnecessary testing, it is important to identify individuals at low CAD risk. The only pretest model available so far to rule out the presence of coronary atherosclerosis in patients with chest pain, but normal coronary arteries, is the minimal risk tool (MRT). Using state-of-the-art statistical methods, we aim to verify the additive predictive value of a set of lipids, derived from targeted plasma lipidomics of suspected CAD patients, to a re-estimated version of the MRT for ruling out the presence of coronary atherosclerosis assessed by coronary CT angiography (CCTA). Two hundred and fifty-six subjects with suspected stable CAD recruited from five European countries within H2020-SMARTool, undergoing CCTA and blood sampling for clinical biochemistry and lipidomics, were selected. The MRT was validated by regression methods and then re-estimated (reMRT). The reMRT was used as a baseline model in a likelihood ratio test approach to assess the added predictive value of each lipid from 13 among ceramides, triglycerides, and sphingomyelins. Except for one lipid, the analysis was carried out on more than 240 subjects for each lipid. A sensitivity analysis was carried out by considering two alternative models developed on the cohort as baseline models. In 205 subjects, coronary atherosclerosis ranged from minimal lesions to overt obstructive CAD, while in 51 subjects (19.9%) the coronary arteries were intact. Four triglycerides and seven sphingomyelins were significantly ( < 0.05) and differentially expressed in the two groups and, at a lesser extent, one ceramide ( = 0.067). The probability of being at minimal risk was significantly better estimated by adding either Cer(d18:1/16:0) ( = 0.01), SM(40:2) ( = 0.04), or SM(41:1) at a lesser extent ( = 0.052) to reMRT than by applying the reMRT alone. The sensitivity analysis confirmed the relevance of these lipids. Furthermore, the addition of SM(34:1), SM(38:2), SM(41:2), and SM(42:4) improved the predictive performance of at least one of the other baseline models. None of the selected triglycerides was found to provide an added value. Plasma lipidomics can be a promising source of diagnostic and prognostic biomarkers in cardiovascular disease, exploitable not only to assess the risk of adverse events but also to identify subjects without coronary atherosclerosis, thus reducing unnecessary further testing in normal subjects.
脂质组学正在兴起,用于心血管疾病生物标志物的发现,循环脂质越来越多地被纳入风险模型以预测心血管事件。此外,特定种类的脂质,如鞘磷脂、神经酰胺和甘油三酯,已被证明与冠状动脉疾病(CAD)的严重程度和斑块特征有关。为避免不必要的检测,识别CAD低风险个体很重要。目前唯一可用于排除胸痛但冠状动脉正常患者存在冠状动脉粥样硬化的检测前模型是最小风险工具(MRT)。我们旨在使用最先进的统计方法,验证从疑似CAD患者的靶向血浆脂质组学中获得的一组脂质,对重新估计的MRT版本的附加预测价值,以排除通过冠状动脉CT血管造影(CCTA)评估的冠状动脉粥样硬化的存在。我们从H2020 - SMARTool项目中的五个欧洲国家招募了256名疑似稳定CAD的受试者,他们接受了CCTA检查,并采集了血液用于临床生物化学和脂质组学分析。通过回归方法对MRT进行验证,然后重新估计(reMRT)。在似然比检验方法中,将reMRT用作基线模型,以评估神经酰胺、甘油三酯和鞘磷脂中的13种脂质各自的附加预测价值。除一种脂质外,对每种脂质均在超过240名受试者中进行了分析。通过将在该队列上开发的两个替代模型作为基线模型进行了敏感性分析。在205名受试者中,冠状动脉粥样硬化程度从最小病变到明显的阻塞性CAD不等,而在51名受试者(19.9%)中冠状动脉完好无损。在两组中,四种甘油三酯和七种鞘磷脂有显著差异(<0.05)表达,程度较轻的还有一种神经酰胺(=0.067)。在reMRT基础上添加Cer(d18:1/16:0)(=0.01)、SM(40:2)(=0.04)或程度较轻的SM(41:1)(=0.052),比单独应用reMRT能更显著地更好估计处于最小风险的概率。敏感性分析证实了这些脂质的相关性。此外,添加SM(34:1)、SM(38:2)、SM(41:2)和SM(42:4)可改善至少一种其他基线模型的预测性能。未发现所选甘油三酯能提供附加价值。血浆脂质组学可能是心血管疾病诊断和预后生物标志物的一个有前景的来源,不仅可用于评估不良事件风险,还可用于识别无冠状动脉粥样硬化的受试者,从而减少正常受试者不必要的进一步检测。